The Food and Drug Administration approved the first drug to address the complete symptom profile of narcolepsy type 1, covering both excessive daytime sleepiness and cataplexy, on Aug. 5.
Prior treatments addressed either sleepiness or cataplexy but not both simultaneously with a single agent, according to FDA. The approval establishes a new treatment standard for a chronic neurological condition.
Narcolepsy type 1 is caused by the loss of hypocretin-producing neurons in the brain and affects an estimated 150,000 to 200,000 Americans, though the condition is frequently underdiagnosed. Patients often wait years before receiving a correct diagnosis.
For Americans living with narcolepsy, the approval simplifies treatment by consolidating symptom management into a single medication. The condition significantly impairs quality of life and poses safety risks for patients who drive, operate machinery or perform other safety-sensitive work.
Cataplexy, which occurs exclusively in narcolepsy type 1, can cause sudden loss of muscle tone ranging from facial drooping to full-body collapse. Episodes are typically triggered by strong emotions such as laughter, surprise or anger.
The specific drug name and manufacturer were not captured in the available FDA release. Pricing and insurance coverage details were not immediately available.
The approval reflects continued FDA focus on neurological conditions that affect workforce productivity and public safety. Sleep disorders are estimated to cost the U.S. economy tens of billions of dollars annually in lost productivity, workplace accidents and healthcare costs.